NICE blow for Novartis' Gilenya could be good news for Biogen
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has again published draft guidance declining to recommend Novartis' Gilenya (fingolimod) for treating relapsing-remitting multiple sclerosis (RRMS). It claims the drug would not be cost-effective.